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Abstract
Background: Thyroid carcinomas are known to harbor oncogenic driver mutations and advances in sequencing
technology now allow the detection of these in fine needle aspiration biopsies (FNA). Recent work by The Cancer
Genome Atlas (TCGA) Research Network has expanded the number of genetic alterations detected in papillary thyroid
carcinomas (PTC). We sought to investigate the prevalence of these and other genetic alterations in diverse subtypes
of thyroid nodules beyond PTC, including a variety of samples with benign histopathology. This is the first clinical
evaluation of a large panel of TCGA-reported genomic alterations in thyroid FNAs.
Results: In FNAs, genetic alterations were detected in 19/44 malignant samples (43 % sensitivity) and in 7/44
histopathology benign samples (84 % specificity). Overall, after adding a cohort of tissue samples, 38/76 (50 %) of
histopathology malignant samples were found to harbor a genetic alteration, while 15/75 (20 %) of benign samples
were also mutated. The most frequently mutated malignant subtypes were medullary thyroid carcinoma (9/12, 75 %)
and PTC (14/30, 47 %). Additionally, follicular adenoma, a benign subtype of thyroid neoplasm, was also found to
harbor mutations (12/29, 41 %). Frequently mutated genes in malignant samples included BRAF (20/76, 26 %) and
RAS (9/76, 12 %). Of the TSHR variants detected, (6/7, 86 %) were in benign nodules. In a direct comparison of the
same FNA also tested by an RNA-based gene expression classifier (GEC), the sensitivity of genetic alterations alone
was 42 %, compared to the 91 % sensitivity achieved by the GEC. The specificity based only on genetic alterations
was 84 %, compared to 77 % specificity with the GEC.
Conclusions: While the genomic landscape of all thyroid neoplasm subtypes will inevitably be elucidated, caution
should be used in the early adoption of published mutations as the sole predictor of malignancy in thyroid. The largest
set of such mutations known to date detects only a portion of thyroid carcinomas in preoperative FNAs in our cohort
and thus is not sufficient to rule out cancer. Due to the finding that variants are also found in benign nodules, testing
only GEC suspicious nodules may be helpful in avoiding false positives and altering the extent of treatment when
selected mutations are found.
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Introduction
With the wide adoption of next-generation sequencing
(NGS) technologies, the number of genome variants and
fusions detected in disease tissues has increased dramat-
ically. The Catalog of Somatic Mutations in Cancer
(COSMIC) database contains >100,000 somatic muta-
tions found across >400,000 tumors [1]. The publicly
accessible ClinVar database contains >170,000 variant
submissions, and >118,000 of these are with clinical
interpretations [2]. The Cancer Gene Atlas (TCGA) pro-
ject has generated extensive genomic data on >11,000
cases across 34 different cancers, including thyroid
cancer [3]. With the discovery of so many variants in
tumor tissues, expectations of their utility in diagnosing
disease are high. In a recent statement by the American
Thyroid Association [4], the suggestion is made that the
expansion of gene sets informed by TCGA variant dis-
covery “will likely improve the diagnostic accuracy of
molecular analyses of thyroid cytology specimens and
offer promise for personalizing surgical therapy, with the
potential for cost and risk reduction in the diagnostic
and therapeutic approaches to treating DTC (differenti-
ated thyroid cancer).” However, the discovery of variants
of uncertain significance (VUS), or variants found in
benign conditions may temper these expectations.
We and others have studied the genomic landscape of
thyroid neoplasms in the pursuit of diagnostic tools for
managing patients with thyroid nodules. Several well-
studied mutations in genes such as BRAF, N-, H-, K-
RAS, and translocations of RET/PTC and PAX8/PPARG
have been evaluated for use in the clinical decision-
making of these patients. In recent years, a growing list
of amino acid substitutions, deletions, insertions, frame-
shifts, truncations, extensions, gene-pair fusions, and
other complex changes have been described in thyroid
cancer [5–12]. The effort implemented by TCGA identi-
fied >500 novel somatic variants in papillary thyroid
carcinoma (PTC), the most common type of thyroid
cancer. While TCGA used malignant tumor vs. matched
normal surgical tissue as the comparison for variant
discovery and analysis, a comparison of malignant vs.
benign thyroid neoplasms was not conducted, and an
understanding of the frequency of these variants in be-
nign thyroid nodules as well as their frequency in fine
needle aspiration (FNA) biopsies is lacking. Here we
used a deep RNA sequencing approach to test the
hypothesis that diagnostic accuracy of thyroid cancer
would be improved by testing a large number of TCGA
and literature curated variants.
The management of thyroid nodules larger than 1 cm
generally includes ultrasound-guided FNA for clinical
decision-making. Evaluation of FNA by cytology leads to
definitive benign or malignant results in 64 % of cases
[13] with both high negative predictive value (NPV)
>95 %, and high positive predictive value (PPV) >98 %
[14–17]. Thirteen percent of cases are non-diagnostic
[13]. Among asymptomatic thyroid nodules, a benign
cytological diagnosis typically averts the need for diag-
nostic surgery. However, 23 % of nodules cannot be
definitively diagnosed [13] and are instead grouped into
one of three cytology indeterminate categories
(Bethesda III, IV, V) [14] according to defined micro-
scopic features. As most cytology indeterminate thy-
roid nodules are pathologically benign, consensus has
arisen on the value of high sensitivity/high NPV value
tests to “rule-out” cancer and safely avoid unnecessary
diagnostic surgery [18].
The advent of molecular testing with an RNA gene
expression classifier (GEC) to rule-out malignancy with
high NPV has greatly reduced the number of diagnostic
thyroid surgeries of cytology indeterminate nodules, as a
majority of these are indeed benign [19–27]. Others have
approached this problem using gene panels whose vari-
ants have been associated with malignancy [28, 29].
Whether these rule-in tests (associated with high specifi-
city/high PPV) could be improved to have high sensitiv-
ity/high NPV for detecting malignancy (and thus
become both a rule-in and rule-out test) has become a
topic of interest. A panel measuring variants in seven
genes failed to achieve the high sensitivity and NPV re-
quired to safely rule-out cancer, as more than half the
cancers did not harbor an identified variant [29]. Panels
measuring an increasing number of variants have been
tested, but not validated in blinded or comprehensive
studies, so their ability to safely rule-out cancer has yet
to be determined.
The large-scale effort employed by TCGA, which gen-
erated exome sequencing, copy number and transcrip-
tional profiling data on a large number of surgical tumor
specimens, was a landmark study in elucidating the gen-
omic landscape of many important cancers [3]. One of
those studied was PTC, the most common thyroid
malignancy [5]. Other types of thyroid cancer were not
analyzed, therefore we extended the TCGA effort, in
part, by evaluating other subtypes of thyroid cancer and
by studying clinically relevant biopsies (thyroid FNA)
collected pre-operatively. Here we report for the first
time the prevalence of many somatic variants reported
by TCGA and others across a wide spectrum of thyroid
neoplasms, including benign lesions, in both preopera-
tive FNA and surgical tissue. We studied FNA samples
that were collected as part of a prospective, multicenter,
blinded cohort, subjected to expert histopathology re-
view [19]; these samples were subsequently blinded and
then tested for known somatic genetic alterations using
the largest panel of variants yet described. We demon-
strate that this panel of 851 somatic variants and 133
somatic fusion gene-pairs has the power to detect only a
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portion of thyroid carcinomas in preoperative FNAs,
raising doubt that such panels can safely rule-out cancer
and avoid unnecessary diagnostic surgery, as has been
suggested [4, 28]. Importantly, some of these genetic
alterations were also commonly found in histopath-
ology benign tumors, suggesting that as variant panels
grow in size, an increasing fraction of benign nodules
will be falsely identified as cancerous unless careful
curation of variants based on their frequencies in be-




FNAs were prospectively collected from 88 patients as
part of a previously reported, blinded multi-center study
(VERA FNA) [19], or from a multi-center consecutive
series of 110 de-identified, pre-operative specimens with
remnant nucleic acids archived by Veracyte’s CLIA
laboratory (CLIA FNA). An additional 85 post-surgical
snap-frozen tissues were procured from multiple clinical
centers across the US, including samples obtained from
Asterand (Detroit, MI), Cureline (South San Francisco,
CA), Proteogenex (Culver City, CA) and CHTN http://
www.chtn.nci.nih.gov/. All clinical protocols were
approved by both central and intuition-specific investi-
gational review boards, and when applicable patients
provided written informed consent. All FNAs were blindly
evaluated by a cytopathologist and were categorized
according to the Bethesda System [14]. Blinded histopath-
ology reference standard labels were determined by a
panel of experts (VERA001 FNA) [19], or by blinded sec-
ondary review to confirm vendor labels (R. Monroe, tissue
cohort) independent of all molecular testing. After sec-
ondary review 63/85 (74 %) of tissues had histopath-
ology truth labels, while 22 were designated as
follicular neoplasm (FN) with uncertain histopathology
(Histo U). CLIA FNA were categorized as GEC Benign
or GEC Suspicious, according to their original Afirma
GEC test result. RNA was extracted using the AllPrep
Micro kit (Qiagen) per the manufacturer’s instructions.
Sequencing libraries were prepared and pooled in
groups of 16 using 10–20 ng of RNA per the manufac-
turer’s instructions using the TruSeq RNA Access kit,
followed by sequencing with a NextSeq 500 instrument
(Illumina) to an average depth of 50 million (from 25
million fragments) using 75 bp paired-end reads.
Detection of genetic alterations
The genomic location of all variants and fusions was ex-
tracted directly from their source publications [5–7, 28, 29]
or determined using reported gene ID, amino acid change
and mutation annotation files (MAF) generated by Broad
Institute, British Columbia Cancer Research Centre, or
Baylor University and obtained through the TCGA public
access portal. When this information was not available,
variants were mapped to their genomic location using
COSMIC, and/or cBioportal databases. The initial panel
was comprised of 987 distinct genetic alterations, including
854 somatic variants and 133 somatic fusion gene-pairs
comprising 524 genes, however three variants could not be
captured by our platform. All genetic alterations included
in the final panel (n = 984) are known to result in protein
level changes, including amino acid substitutions, deletions,
insertions, frameshifts, truncations, extensions, and other
complex changes. Copy number alterations were not mea-
sured. While this study focused exclusively on curated som-
atic gene alteration reports [5–7, 28, 29], it is possible that
some mutations are present in nodules due to germline
variation. Samples were scored positive using the variant
and fusion detection pipelines described below.
Reads were aligned to the reference genome, build 37,
via STAR v2.4.1b [30] using state of the art best practices
for variant and fusion detection as follows; splice-aware
alignments used annotations of all known splice junc-
tions from Ensembl 75. De-duplication was carried out
with picard v1.123 MarkDuplicates and aligned reads
were processed in GATK v3.3. Variants were detected
using the GATK Haplotype Caller [31]. Low quality calls
were filtered out with GATK VariantFiltration. Fusions
were detected from STAR outputs using the Bioconduc-
tor package chimera [32] and all filtering settings turned
on. Asymptotic standard logit intervals were used to
calculate positive predictive values (PPV) and negative
predictive values (NPV) along with their associated con-
fidence intervals as previously described [33]. Whenever
a zero occurs in a two-by-two contingency table, this
method returns estimated adjusted logit intervals that
are non-zero.
Results
Our analysis of genetic alterations using genome-wide
transcriptome sequencing included 133 fusion pairs and
854 somatic variants. Of these, 133/133 (100 %) of
fusions and 851/854 (99.6 %) of variants were detectable
by our RNA sequencing effort. Only three variants could
not be captured, because they are located at two gen-
omic sites within the non-transcribed promoter region
of the TERT gene. Hence, our results center on a final
panel of 984 distinct genetic alterations spanning 524
genes. We measured sequencing quality metrics in this
study, capturing a median of 48 million paired-end reads
and 37 million aligned reads per sample, and computed
the range of variants covered at various read depths
(Additional file 1). We measured the median read-depth
per variant across the pathology subtypes and found
variation in coverage, consistent with biological variation
in expression of transcripts harboring the genetic
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variants (Additional file 2). Given this biological vari-
ation among subtypes, it is important to assess individ-
ual level coverage. We found 93 % of the 851 variant
locations have at least one sample with 20-fold cover-
age (Additional file 1). Variants discussed in this paper
were identified using standard variant calling methods
(GATK) and for the sake of comparison, additional var-
iants identified at a more sensitive but less specific set-
ting using another variant calling method (SamTools)
are reported in Additional file 3.
We evaluated an FNA cohort with surgical truth and
found that 19/44 of histopathology malignant samples
scored positive for at least one of the genetic alter-
ations, corresponding to 43 % sensitivity (Fig. 1,
Table 1). Histopathology benign FNAs scored positive
in 7/44 cases, corresponding to 84 % specificity
(Table 1). The prevalence of malignant samples in this
study cohort was 50 %, resulting in estimates of NPV
of 60 % (53–66, CI), and PPV of 73 % (56–85, CI). The
performance of the molecular panel was also evaluated
for each Bethesda cytology category (Tables 2, 3, 4, 5
and 6) using two cancer prevalences (Table 1). While
the number of samples was low in many groups, in
cytology malignant (Bethesda VI) where the highest
proportion of mutated samples was observed, 14/24
samples had a detectable variant or fusion, corre-
sponding to 58 % sensitivity.
In the post-surgical tissue cohort, 19/32 histopathology
malignant samples had a detectable genetic alteration
(59 % sensitivity), while 8/31 histopathology benign sam-
ples scored positive, a specificity of 74 % (Fig. 2). A single
GNAS variant was observed to occur in a follicular aden-
oma. As this variant has been considered to be a marker
for benign nodules, we excluded it from performance calcu-
lations to avoid falsely lowering the estimate of specificity.
The frequency of malignant samples in this small cohort
was 51 % and its NPV was estimated at 64 % (53–74, CI),













Sensitivity, 43% (28-59); Specificity, 84% (70-93); PPV, 73% (56-85); NPV, 60% (53-66)
Prevalence of malignant lesions, 50%. Estimated performance when prevalence equals 24%: 
PPV, 46% (29-65%); NPV, 82% (78-86).
Fig. 1 Performance across VERA FNA data set (n = 88) and genetic alterations observed by cytology (a) and histology subtype (b). The width of each
band of the circos plots is proportional to the number of samples harboring a particular variant or fusion. A complete list of all variants and fusions
detected can be found in Additional files 3 and 7. Abbreviations: AUS/FLUS atypia of undetermined significance/follicular lesion of undetermined
significance, BFN benign follicular nodule, Cyto B cytology benign, Cyto M cytology malignant, FA follicular adenoma, FC follicular carcinoma, FN/SFN
follicular neoplasm or suspicious for neoplasm, FVPTC follicular variant of papillary carcinoma, HCA Hurthle cell adenoma, HCC Hurthle cell carcinoma,
LCT lymphocytic thyroiditis, MTC medullary thyroid carcinoma, NHP nodular hyperplasia, PTC papillary thyroid carcinoma, PTC-TCV papillary thyroid
carcinoma-tall cell variant, SFM suspicious for malignancy, WDC-NOS well-differentiated carcinoma-not otherwise specified
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We also studied a consecutive FNA series (n = 110)
processed through our CLIA laboratory. This clinically
representative cohort was comprised primarily of
cytology indeterminate samples, and was evaluated to
characterize the frequency of somatic genetic alter-
ations in a broad, multicenter, US population (Fig. 3).
In CLIA FNA with AUS/FLUS cytology, (Bethesda III)
9/52 (17 %) of samples scored positive for a genetic
alteration, similar to FNAs with FN/SFN cytology
(Bethesda IV) where 4/24 samples harbored a variant
(17 %). Since histopathology truth was not available
for any CLIA FNA, we could not compute sensitivity,
specificity, NPV or PPV.
We compared the results obtained from testing for
genetic alterations with results obtained from testing
with the Afirma GEC, an RNA-based molecular classifier
designed to rule-out malignancy with 90 % sensitivity
and 94–95 % NPV [19]. The test reports either a GEC
Benign or GEC Suspicious result. In a subset of 86
VERA FNA samples with truth labels and both GEC and
genetic alteration results available, testing for genetic
alterations alone identified 42 % of malignant samples,
compared to the GEC, which identified 91 % of the true
malignant samples (Fig. 4). These results are consistent
with previously published reports confirming high sensi-
tivity of the GEC [19, 21–26, 34]. In this cohort, testing
for genetic alterations resulted in 84 % specificity, com-
pared to the GEC, which resulted in 77 % specificity,
higher than the 52 % reported in a large, prospective,
blinded multicenter study [19]. The proportion of
detected genetic alterations was far higher in samples
with GEC Suspicious results; 22/49 (45 %) than those
with GEC Benign results (3/37, 8 %), resulting in an
overall PPV of potentially >60 % when cancer prevalence
is 40 %, as is the case for Afirma Suspicious nodules.
This suggests that variant testing would have greater
clinical utility on GEC Suspicious FNAs where the
detection of genetic alterations may alter the extent of
treatment when selected mutations are found. Con-
versely, no cancer missed by the GEC had a genetic
alteration, suggesting that mutational testing on this
GEC Benign cohort would not have identified true ma-
lignant nodules and would therefore lack clinical utility.
We wanted to get a global view of genetic alterations
in both of our cohorts. After combining FNA (n = 88)
and tissue (n = 63) samples with truth labels, 38/76
(50 %) of histopathology malignant samples were
found to harbor a genetic alteration, and 15/75 (20 %)
of the histopathology benign samples were also mu-
tated (Additional file 4). The most frequently mutated
subtypes were MTC (9/12, 75 %), PTC (14/30, 47 %),
and FA (12/29, 41 %). Frequently mutated genes in
malignant samples included BRAF 21/76 (28 %), found
predominantly in cytology malignant samples (Fig. 1).
In FNAs with a histopathology diagnoses of PTC,
FVPTC or PTC-TCV, 13/37 (35 %) were positive for
the BRAF V600E mutation, and in surgical tissues
with these same diagnoses, 7/12 (54 %) harbored this
mutation (Additional file 5). Also frequently mutated
was TSHR, found in 6/75 (8 %) of histology benign
samples and only once in a malignant follicular carcin-
oma (Figs. 1 and 2).
Table 1 Performance comparison across sample cohorts
Performance of genetic alterations (Variants and Fusions)
Cancer prevalence used in calculation
PPV NPV
Sample cohort Sensitivity Specificity 24 % 40 % 24 % 40 %
All VERA FNA (n = 88) 43 % (28–59) 84 % (70–93) 46 % (29–65) 64 % (46–79) 82 % (78–86) 69 % (62–75)
AUS/FLUS & FN/SFN only
VERA FNA (n = 22)
33 % (1–91) 84 % (60–97) 40 % (9–82) 58 % (17–90) 80 % (64–90) 65 % (45–81)
Tissue (n = 63) 59 % (41–76) 74 % (55–88) 42 % (27–58) 61 % (44–75) 85 % (78–90) 73 % (63–81)
Combined VERA FNA
and tissue (n = 151)
50 % (38–62) 80 % (69–88) 44 % (32–57) 63 % (50–73) 84 % (80–87) 71 % (65–76)
Table 2 FNA performance per cytology group
Performance on Cytology Benign (n = 30)






Sensitivity, 0 % (0–46); Specificity, 83 % (63–95); PPV, 16 % (5–50); NPV, 79 %
(73–85), prevalence of malignant lesions, 20 %. Estimated performance when
malignancy is prevalent at 6 %: PPV, 5 % (1–20); NPV, 94 % (91–96)
Table 3 FNA performance per cytology group
Performance on AUS/FLUS (n = 12)






Sensitivity, 0 % (0–98); Specificity, 91 % (59–100); PPV, 16 % (4–45); NPV, 93 %
(87–97), prevalence of malignant lesions, 8 %. Estimated performance when
malignancy is prevalent at 24 %: PPV, 40 % (12–74); NPV, 81 % (66–90)
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Given the rarity of most variants measured in this
cohort, we investigated the effect of sample size and its
impact on mutation rate estimation. At a true underlying
mutation rate of 3 %, 95 % confidence intervals are large
for sample sizes below 100 (Additional file 6), suggesting
that larger cohorts would be required to achieve more
precise estimates. However, the large proportion of ma-
lignant samples with no variant detected (50 %), along
with the reasonably high rate of benign nodules with a
variant detected (20 %) cannot be explained solely by an
under-representation of these variants in a small sample
size cohort. The variant detection rate observed in be-
nign nodules limits the performance of the panel, in par-
ticular confers a specificity penalty that limits the panel’s
ability to attain both high sensitivity and high specificity.
Discussion
In this study we demonstrate that interrogation of a
large number of somatic genomic alterations, as re-
ported by TCGA [5, 6] and others [7, 28], is limited in
its ability to detect cancer with high sensitivity when
applied to a diverse set of thyroid carcinomas. Published
data from TCGA shows 59.7 % of their PTC tissue co-
hort harbored a BRAF mutation, similar to the 54 % we
found for the PTC tissues in our study. Despite this
similarity, extension of our study to other subtypes and
to FNAs reveals that of the histopathology malignant
samples, 41 % of tissues and 57 % of FNAs scored nega-
tive for any of the 984 genetic alterations tested. These
results are consistent with the observations of others [4]
noting that a panel of the 17 most common genetic
alterations [29] failed to detect 53 % of carcinomas with
Bethesda III or IV cytology. Despite significant overlap
with the mutations evaluated here and in those of other
smaller panels [35, 36], a recent single-center study that
was not blinded, reported both high sensitivity and high
specificity measuring similar genetic alterations on FN/
SFN [28] and/or AUS/FLUS samples [37]. While the
difference in sensitivity may be partially explained by the
measurement of very rare variants in these small co-
horts, which is expected statistically to result in a wide
range in performance, this would not explain the differ-
ence in specificity, as we detect many of the same
variants in benign nodules. In addition, the impact of
blinded versus unblinded histopathology truth labels, or
local histopathology diagnostic trends among challen-
ging neoplasms, may account for differing performance
among similar genomic panels. Collectively, our results
and those of other groups [29, 35, 36, 38, 39] do not
provide sufficient evidence to support the notion that
Table 4 FNA performance per cytology group
Performance on FN/SFN (n = 10)






Sensitivity, 50 % (1–99); Specificity, 75 % (35–97); PPV, 33 % (7–76); NPV, 86 %
(59–96), prevalence of malignant lesions, 20 %. Estimated performance when
malignancy is prevalent at 24 %: PPV, 39 % (9–80); NPV, 83 % (53–95)
Table 5 FNA performance per cytology group
Performance on SFM (n = 12)






Sensitivity, 36 % (11–69); Specificity, 100 % (3–100); PPV, 92 % (76–98); NPV,
9 % (4–17), prevalence of malignant lesions, 92 %. Estimated performance
when malignancy is prevalent at 24 %: PPV, 25 % (8–53); NPV, 77 % (58–88).
Estimated performance when malignancy is prevalent at 62 %: PPV, 64 %
(32–85); NPV, 39 % (21–59)
Table 6 FNA performance per cytology group
Performance on Cytology Malignant (n = 24)






Sensitivity, 58 % (37–78); Specificity, NA% (NA); PPV, NA% (NA); NPV, NA%
(NA), prevalence of malignant lesions, 100 %. Estimated performance when












Sensitivity, 59% (41-76); Specificity, 74% (55-88); PPV, 70% (55-82); 
NPV, 64% (53-74), prevalence of malignant lesions, 51%. 
Estimated performance when prevalence equals 24%: PPV, 42% (27-58); 
NPV, 85% (78-90).
Fig. 2 Performance across tissue data set (n = 63) showing genetic
alterations observed per subtype. Abbreviations: ATC anaplastic
thyroid carcinoma, BFN benign follicular nodule, CN colloid nodule,
FA follicular adenoma, FC follicular carcinoma, FVPTC follicular variant
of papillary carcinoma, HCA Hurthle cell adenoma, HCC Hurthle cell
carcinoma, Histo U histology uncertain, LCT lymphocytic thyroiditis,
MTC medullary thyroid carcinoma, NHP nodular hyperplasia, NML
normal thyroid, PTC papillary thyroid carcinoma, PTC-TCV papillary
thyroid carcinoma-tall cell variant, SFM suspicious for malignancy,
WDC-NOS well-differentiated carcinoma-not otherwise specified
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detection of known genetic alterations alone has suffi-
cient power at this time to safely rule out malignancy in
all thyroid subtypes. Additional studies in larger FNA
cohorts are clearly needed to evaluate further the utility
of mutational testing in ruling out malignancy.
This analysis of a broad cohort of expertly diagnosed
thyroid neoplasms establishes for the first time that re-
cent TCGA-reported oncogenic driver alterations are
commonly found in nodules with benign histopathology.
While we recognize that our sample cohorts are of mod-
est size and that more accurate mutation-detection
methods may be developed and applied in the future,
the overall mutation frequencies observed in histopath-
ology benign FNA (16 %) and benign tissues (26 %) sug-
gest that the use of panels with increasingly larger
numbers of discovered variants may not help rule out
malignancy in thyroid nodules. Without proper curation,
such panels may increase the frequency of variant detec-
tion in benign nodules and generate false positive re-
sults. Many markers detected in the current study have
been reported to vary widely in their individual specifi-
city to detect malignancy [29, 39, 40]. Unfortunately,
variants with high specificity such as BRAF V600E or
RET/PTC fusions are the exception rather than the rule.
Somatic genetic alterations such as those found in
NRAS, HRAS, and PAX/PPARG are known to occur in
benign nodules [35, 41–43]. The long-term significance
of these mutations in benign nodules has not been fully
studied [44], and some have suggested that these rep-
resent pre-malignant lesions [29, 35, 36, 45, 46].
Despite this suggestion, no clinical evidence exists to
demonstrate that today’s mutation-positive, but
histopathology-benign tumors have a clinically mean-
ingful rate of developing into cancer, or a higher rate
of malignant transformation than mutation-negative
benign lesions [44]. Thus, no evidence exists that
patients benefit from the identification and treatment
of mutation-positive benign nodules. In contrast,
there may be a role in identifying variants in GEC
Suspicious nodules, as these genomic alterations may
alter the extent of treatment when selected muta-
tions are found.
Because many gene variants are also detected in our
histologically benign nodules, an approach whereby any
mutation-positive nodule is designated as “test-positive”
has the risk of artificially and erroneously raising the fre-
quency of suspected thyroid carcinoma, thus negatively
impacting patients who could have benefited from a
watch-and-wait approach. An additional concern is that
a number of studies in the literature use mutation status
to assign a diagnosis, bypassing blinded expert review to
confirm that a mutation positive nodule was indeed
histopathology malignant [36, 47]. This chicken-egg con-












PPA 30% (18-45); NPA, 92% (82-97). 
Fig. 3 Variants detected in CLIA FNA data set (n = 110) showing
genetic alterations observed per subtype. Abbreviations: AUS/FLUS
atypia of undetermined significance/follicular lesion of
undetermined significance, Cyto B cytology benign, Cyto
NA cytology category not available, FN/SFN follicular neoplasm
or suspicious for neoplasm, NPA negative percent agreement,
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True . Neg . 30 6 36
False Pos. 3 4 7
True Pos. 18 18
False Neg. 21 4 25


















Fig. 4 Comparison of genetic alteration test results versus an RNA
gene expression classifier (GEC) in FNA samples tested with both
methods (n = 86). Abbreviations: False Pos false positive, False Neg
false negative, True Pos true positive, True Neg true negative
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and specificity, as truly benign nodules are declared ma-
lignant based on mutation status [29, 36, 47]. A recent
report indicates that a diagnosis changes from benign to
malignant in 30 % of RAS mutated cases when the path-
ologist is aware that a mutation is present [47].
Our approach measures gene variants found only in
expressed genes, and therefore has the advantage of cap-
turing biological processes such as allele-specific gene
expression and imprinting. For example, variants found
in DNA may have little relevance to a disease if the gene
harboring the variant is not expressed in the tissue being
sampled. This could be due to general lack of expression
in a particular tissue, or could be due to a parental allele-
of-origin effect. Our finding that gene transcripts harbor-
ing these variants shows expression patterns that differ
amongst thyroid subtypes is consistent with the power of
this approach to capture potential biological processes
(Additional file 2). Thus in contrast to measuring variants
in DNA, our RNA transcriptome approach allows the de-
tection of variants and fusions that have the potential to
be biologically relevant and clinically meaningful.
As some genomic variants are modestly or highly asso-
ciated with thyroid malignancy, there may be value to
their detection when their presence would increase the ex-
tent of initial surgery from a hemi-thyroidectomy to a
total thyroidectomy to avoid the need for a second com-
pletion thyroidectomy surgery amongst those with cancer.
Alternatively, in seven studies evaluating a total of 730 pa-
tients whose thyroid nodules were tested with the highly
sensitive RNA-based GEC, 49 % were scored as benign
[21–25, 34]. These patients are considered for clinical
follow-up in lieu of diagnostic surgery with high accuracy
[26], a data-driven approach that spares unnecessary mor-
bidity. The implementation of a genomic panel in patients
destined for surgery may reduce the need for this second
(completion) surgery [48], especially when positive for
highly specific variants.
Conclusions
Our studies in this cohort show that evaluating thyroid
nodules for genetic variants increases the risk of false posi-
tives without rescuing any GEC false negatives. Our data
suggest that even when testing with a large variant panel
alone, a negative mutation result does not reasonably ex-
clude cancer. However, our data also indicates that when
malignancy cannot be ruled out with variant panels, a
GEC benign result can first be implemented to safely ex-
clude patients without malignancy and patients with sus-
picious GEC results may then benefit from evaluation
with a genomic variant panel, if this new information re-
sults in a change to clinical management. A majority of
nodules with indeterminate cytology prove benign on
post-operative histopathology. Hence, tests that use gen-
omic profiling to rule-out cancer with high sensitivity have
demonstrated clinical utility in the management of cy-
tology indeterminate nodules [19–26].
Given the extremely low frequency of many of the
variants and fusions tested here, accurate estimates of
test performance will require the testing of many more
patient samples and cohorts. Hopefully, carefully con-
ducted multi-center and blinded studies, with expert
pathology annotation, will be forthcoming in the near
future to shed light on the mutational spectrum of both
benign and malignant thyroid nodules.
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